United States 111th Congress Status: Died

SRES 161 — A resolution recognizing June 2009 as the first National Hereditary Hemorrhagic Telangiecstasia (HHT) month, established to increase awareness of HHT, which is a complex genetic blood vessel disorder that affects approximately 70,000 people in the United States.

Last action — Submitted in the Senate, considered, and agreed to without amendment and with a preamble by Unanimous Consent. (consideration: CR S5885; text as passed Senate: CR S5885; text of measure as introduced: CR S5877)

Track this bill free

No card. One bill, free forever — alerts when it moves.

  1. ✓
    Introduced
  2. ✓
    In Committee
  3. ✓
    Passed Senate
  4. ✓
    Passed House
  5. Died in session

This bill died with 111th Congress. It reached “Passed House” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.

This bill is no longer active — its legislative session has ended, so there is no live prognosis. It would have to be reintroduced in the current session to move again.

Summary

Expresses support for the designation of June 2009 as National Hereditary Hemorrhagic Telangiecstasia (HHT) month. Recognizes: (1) the need to pursue research to find better treatments and a cure for HHT; (2) the HHT Foundation International as the only U.S. advocacy organization working to find a cure for HHT while saving the lives and improving the well-being of individuals and families affected; (3) the importance of comprehensive care centers in providing complete care and treatment for HHT patients; (4) that stroke, lung, and brain hemorrhages can be prevented through early diagnosis, screening, and treatment of HHT; (5) that severe hemorrhages in the nose and gastrointestinal tract can be controlled through intervention and that heart failure can be managed through proper diagnosis and treatments of HHT; and (6) that a leading medical and academic institution estimated that $6.6 billion of one-time health care costs can be saved through aggressive management of HHT in the at-risk population. Acknowledges the need to identify the approximately 90% of the HHT population that has not yet been diagnosed and that is at risk for death or disability due to sudden rupture of the blood vessels in major organs in the body.

Bill Text

We don't have the full text on file for this bill yet.

Read SRES 161 on the official United States source →

Action History

  1. Submitted in the Senate, considered, and agreed to without amendment and with a preamble by Unanimous Consent. (consideration: CR S5885; text as passed Senate: CR S5885; text of measure as introduced: CR S5877)

Sponsorship breakdown

Export CSV (upgrade) →

0 sponsors · 0 co-sponsors · 547 not signed on

Sponsors (0)

None.

Co-sponsors (0)

None.

Not signed on (547)

547 members have not signed on to this bill.

Show all 547 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Subjects

healthcare health-insurance
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

What does SRES 161 do?
Expresses support for the designation of June 2009 as National Hereditary Hemorrhagic Telangiecstasia (HHT) month. Recognizes: (1) the need to pursue research to find better treatments and a cure for HHT; (2) the HHT Foundation International as the only U.S. advocacy organization working to find a cure for HHT while saving the lives and improving the well-being of individuals and families affected; (3) the importance of comprehensive care centers in providing complete care and treatment for HHT patients; (4) that stroke, lung, and brain hemorrhages can be prevented through early diagnosis, screening, and treatment of HHT; (5) that severe hemorrhages in the nose and gastrointestinal tract can be controlled through intervention and that heart failure can be managed through proper diagnosis and treatments of HHT; and (6) that a leading medical and academic institution estimated that $6.6 billion of one-time health care costs can be saved through aggressive management of HHT in the at-risk population. Acknowledges the need to identify the approximately 90% of the HHT population that has not yet been diagnosed and that is at risk for death or disability due to sudden rupture of the blood vessels in major organs in the body.
What is the current status of SRES 161?
This bill died with 111th Congress. It reached “Passed House” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
Where can I track SRES 161?
Track SRES 161 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on SRES 161

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of SRES 161

Last checked for changes about 11 hours ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →